Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial

OBJECTIVE: The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial (ClinicalTrials.gov reg. no. NCT01179048) demonstrated a reduced risk of cardiovascular (CV) events for patients with type 2 diabetes who received the glucagon-like peptide 1 recepto...

Descripción completa

Detalles Bibliográficos
Autores principales: Buse, John B., Bain, Stephen C., Mann, Johannes F.E., Nauck, Michael A., Nissen, Steven E., Pocock, Stuart, Poulter, Neil R., Pratley, Richard E., Linder, Martin, Monk Fries, Tea, Ørsted, David D., Zinman, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2020
Materias:
Cardiovascular and Metabolic Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305014/
https://www.ncbi.nlm.nih.gov/pubmed/32366578
http://dx.doi.org/10.2337/dc19-2251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305014/
https://www.ncbi.nlm.nih.gov/pubmed/32366578
http://dx.doi.org/10.2337/dc19-2251

Ejemplares similares